Towards Healthcare Research & Consulting

Antibody Contract Manufacturing Key Players and their Developments

Date : 07 May 2026

Who are the Antibody Contract Manufacturing Market Top Companies and What are Their Offerings?

Antibody Contract Manufacturing Market Companies are Lonza Group, Samsung Biologics, FUJIFILM Diosynth Biotechnologies, WuXi Biologics, Siegfried Holding, Thermo Fisher Scientific (Patheon), AGC Biologics

Companies Headquarters Antibody Contract Manufacturing Solutions
Lonza Group Basel, Switzerland Ibex Solutions
Samsung Biologics Incheon, South Korea S-DUAL
FUJIFILM Diosynth Biotechnologies College Station, Tokyo Specialized one-stop shop for ADC production
WuXi Biologics Wuxi, China WuXiBody bispecific platform
Siegfried Holding Zofingen, Switzerland Antibody drug substance and sterile drug product manufacturing
Thermo Fisher Scientific (Patheon) Waltham, U.S. Accelerator Drug Development Platform
AGC Biologics Seattle, U.S. Diverse mammalian and microbial production systems
Catalent, Inc. Bridgewater, U.S. GPEx Lightning cell line technology and SMARTag ADC platform
Merck KGaA (MilliporeSigma) Burlington, Darmstadt Specialized CDMO services for ADC bioconjugation and biosafety testing solutions
Boehringer Ingelheim (BioXcellence) Ingelheim, Germany Integrated DNA-to-finished-dosage services

What are the Recent Developments in the Antibody Contract Manufacturing Market?

  • In April 2026, the Antibody Developability Assessment Services was launched by Biointron, which is a contract research organization specializing in antibody discovery, production, and optimization. The high-throughput antibody production and full panel of tests are combined in this platform.
  • In April 2026, GMP certification from South Korea Ministry of Food and Drug Safety (MFDS) was granted to WuXi Biologics (2269.HK), which is a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), for its 3 manufacturing facilities in Wuxi, namely Drug Product Facility 2 (DP2), Drug Product Packaging Center (DPPC), and Drug Substance Facility 5 (MFG5). This certification will promotes end‑to‑end commercial manufacturing services of WuXi Biologics for drug substance, drug product, and a bispecific antibody for biliary tract cancer treatment.

Antibody Contract Manufacturing Market Value Chain Analysis

R&D

  • The R&D of the antibody contract manufacturing focuses on the development of site-specific conjugation platforms, high-titer mammalian cell lines, and automated continuous bioprocessing.
  • Key players: Lonza Group, WuXi Biologics, Samsung Biologics.

Formulation and Final Dosage Preparation

  • The formulation and final dosage preparation of antibody contract manufacturing involves precise stabilization of drug substances into high-concentration liquids, followed by aseptic fill-finish into vials or pre-filled syringes.
  • Key players: Lonza Group, WuXi Biologics, Thermo Fisher Scientific (Patheon).

Patient Support and Services

  • User-friendly delivery devices, drug supply continuity, and patient-specific logistics are provided in the patient support and services of the antibody contract manufacturing.
  • Key players: Thermo Fisher Scientific (Patheon), Lonza Group, Catalent, Inc.

Market Growth

The global antibody contract manufacturing market size was estimated at USD 18.6 billion in 2025 and is predicted to increase from USD 20.4 billion in 2026 to approximately USD 46.94 billion by 2035, expanding at a CAGR of 9.7% from 2026 to 2035.

Antibody Contract Manufacturing Market Size is USD 20.4 Billion in 2026.